The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway

Drug repositioning has recently emerged as a strategy for developing new treatments at low cost. In this study, we used a library of approved drugs to screen for compounds that suppress cardiomyocyte hypertrophy. We identified the antiplatelet drug sarpogrelate, a selective serotonin-2A (5-HT(2A)) r...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Kana, Sunagawa, Yoichi, Funamoto, Masafumi, Honda, Hiroki, Katanasaka, Yasufumi, Murai, Noriyuki, Kawase, Yuto, Hirako, Yuta, Katagiri, Takahiro, Yabe, Harumi, Shimizu, Satoshi, Sari, Nurmila, Wada, Hiromichi, Hasegawa, Koji, Morimoto, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708651/
https://www.ncbi.nlm.nih.gov/pubmed/34959669
http://dx.doi.org/10.3390/ph14121268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708651/
https://www.ncbi.nlm.nih.gov/pubmed/34959669
http://dx.doi.org/10.3390/ph14121268

Ejemplares similares